Suja Life Receives Bullish Ratings After IPO Quiet Period
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: seekingalpha
- Wall Street Bullish Ratings: Suja Life (SUJA) received a clean sweep of bullish ratings from Wall Street after the IPO quiet period ended, with Goldman Sachs issuing a Buy rating and a price target of $31, reflecting strong market confidence in its growth potential.
- New Growth Vector in Functional Beverages: Jefferies analyst noted that juice is being reframed around functional benefits and convenient formats, creating a new growth vector within a $19 billion category, positioning Suja Life favorably as distribution expands and multipacks grow.
- Valuation Advantage: Gajrawala highlighted that Suja Life trades at a valuation of 13X the 2027 EBITDA estimate, which is a discount compared to high-growth peers, indicating its competitive edge and attractiveness in the market.
- Strong Market Performance: Shares of Suja Life (SUJA) jumped 6.9% in premarket trading to $16.50, approaching the IPO price of $21, demonstrating investor optimism regarding its future development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUJA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUJA
Wall Street analysts forecast SUJA stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 13.990
Low
Averages
High
Current: 13.990
Low
Averages
High
About SUJA
Suja Life, Inc. is a beverage platform. The Company operates at the intersection of health, taste, and trust, offering cold-pressed juices, wellness shots, and functional sodas that have become an essential part of consumers' everyday routines. Its brands include Suja Organic, Vive Organic, and Slice. Suja Organic is its flagship brand, known for its organic cold-pressed juices and wellness shots.it includes a green juice platform, boosted juice platform, refreshers platform, and wellness shots platform. Vive Organic is a wellness shot brand, known for the functional shot category with its doctor-crafted formulations and redefining how consumers approach proactive wellness. It offers an immunity boost platform, energy boost platform, and pure boost platform. Slice offers an original better-for-you soda, made with 10% real fruit juice and also with prebiotics, probiotics, postbiotics, reduced sugar, and no artificial ingredients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Suja Life Receives Bullish Ratings After IPO Quiet Period
- Wall Street Bullish Ratings: Suja Life (SUJA) received a clean sweep of bullish ratings from Wall Street after the IPO quiet period ended, with Goldman Sachs issuing a Buy rating and a price target of $31, reflecting strong market confidence in its growth potential.
- New Growth Vector in Functional Beverages: Jefferies analyst noted that juice is being reframed around functional benefits and convenient formats, creating a new growth vector within a $19 billion category, positioning Suja Life favorably as distribution expands and multipacks grow.
- Valuation Advantage: Gajrawala highlighted that Suja Life trades at a valuation of 13X the 2027 EBITDA estimate, which is a discount compared to high-growth peers, indicating its competitive edge and attractiveness in the market.
- Strong Market Performance: Shares of Suja Life (SUJA) jumped 6.9% in premarket trading to $16.50, approaching the IPO price of $21, demonstrating investor optimism regarding its future development.
See More
May IPO Market Rebounds with $11.5 Billion Raised
- Record Fundraising: Thirteen IPOs raised a total of $11.5 billion in May, marking the highest monthly proceeds since November 2021, indicating a robust market recovery and renewed investor confidence.
- Large Deals Dominate: AI chipmaker Cerebras led the market with a $5.6 billion deal, while geothermal energy developer Fervo and data center REIT Blackstone Digital Infrastructure Trust also raised over $1 billion each, highlighting strong demand in AI-related sectors.
- Strong IPO Performance: Traditional IPOs averaged a 5% return from their offer prices, with about half closing above their issue prices, reflecting positive market sentiment towards new listings, particularly with Fervo and BXDC showing strong first-day gains.
- Optimistic Future Outlook: With new filings from companies like SpaceX, more IPO transactions are expected in the coming months as the market broadens, and strong returns alongside a solid pipeline set the stage for a busy IPO calendar ahead.
See More
Latest Rating Changes on Wall Street
- Executive Rating Updates: Goldman Sachs initiates coverage on HawkEye 360 with a Buy rating, emphasizing its status as a profitable RF signals intelligence satellite operator, which is expected to achieve substantial revenue and earnings growth, reflecting strong confidence in its market potential.
- Dell Rating Upgrade: Morgan Stanley upgrades Dell from Underweight to Equal Weight, admitting prior market expectations were incorrect, highlighting Dell's superior supply chain management and execution compared to peers, enabling effective capture of critical demand and market share gains.
- MedTech Company Upgrade: Wells Fargo upgrades Tandem Diabetes Care to Overweight, citing an attractive risk/reward profile in the medical technology sector, indicating optimism about its future growth potential.
- Microsoft Market Performance Initiation: Citizens initiates Microsoft with a Market Outperform rating and a $550 price target, reflecting strong market performance potential despite a 7% decline year-to-date, indicating resilience in its business model.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Suja Life Raises $187 Million in IPO at Low End of Range
- Funding Size: Suja Life successfully raised $187 million by offering 8.9 million shares at $21 each, which is at the low end of the $21 to $24 range, indicating sustained market interest and demand for health-oriented beverages.
- Product Portfolio: The company focuses on functional and health-oriented drinks, with brands including Suja Organic, Vive Organic, and Slice, offering cold-pressed juices, wellness shots, and functional sodas designed for various consumption occasions, enhancing its competitive edge in the market.
- Production Capacity: Suja Life operates a vertically integrated cold-pressed beverage manufacturing facility in North America, ensuring high product quality and supply chain stability, thereby strengthening its position in the rapidly growing health beverage market.
- IPO Details: Based in Oceanside, CA, Suja Life will trade on Nasdaq under the ticker SUJA, with joint bookrunners including Goldman Sachs, Jefferies, and William Blair, reflecting strong backing in the capital markets.
See More
Suja Life Plans $200 Million IPO for Health-Oriented Beverage Platform
- IPO Fundraising Goal: Suja Life aims to raise $200 million by offering 8.9 million shares (2% secondary) at a price range of $21 to $24, intending to enhance its competitiveness in the health beverage market.
- Product Diversification: The company offers cold-pressed juices, wellness shots, and functional sodas through its Suja Organic, Vive Organic, and Slice brands, catering to various consumption occasions and solidifying its market position in functional beverages.
- Financial Performance: Suja Life reported $327 million in revenue for the 12 months ending December 31, 2025, indicating strong growth potential in the health beverage sector, with the IPO expected to provide funding for future expansion.
- Listing Plans: Suja Life plans to price its IPO during the week of May 4, 2026, and list on Nasdaq under the ticker SUJA, which is anticipated to attract investor interest in the health beverage industry.
See More
Suja Life Receives Bullish Ratings After IPO Quiet Period
- Wall Street Bullish Ratings: Suja Life (SUJA) received a clean sweep of bullish ratings from Wall Street after the IPO quiet period ended, with Goldman Sachs issuing a Buy rating and a price target of $31, reflecting strong market confidence in its growth potential.
- New Growth Vector in Functional Beverages: Jefferies analyst noted that juice is being reframed around functional benefits and convenient formats, creating a new growth vector within a $19 billion category, positioning Suja Life favorably as distribution expands and multipacks grow.
- Valuation Advantage: Gajrawala highlighted that Suja Life trades at a valuation of 13X the 2027 EBITDA estimate, which is a discount compared to high-growth peers, indicating its competitive edge and attractiveness in the market.
- Strong Market Performance: Shares of Suja Life (SUJA) jumped 6.9% in premarket trading to $16.50, approaching the IPO price of $21, demonstrating investor optimism regarding its future development.
See More
May IPO Market Rebounds with $11.5 Billion Raised
- Record Fundraising: Thirteen IPOs raised a total of $11.5 billion in May, marking the highest monthly proceeds since November 2021, indicating a robust market recovery and renewed investor confidence.
- Large Deals Dominate: AI chipmaker Cerebras led the market with a $5.6 billion deal, while geothermal energy developer Fervo and data center REIT Blackstone Digital Infrastructure Trust also raised over $1 billion each, highlighting strong demand in AI-related sectors.
- Strong IPO Performance: Traditional IPOs averaged a 5% return from their offer prices, with about half closing above their issue prices, reflecting positive market sentiment towards new listings, particularly with Fervo and BXDC showing strong first-day gains.
- Optimistic Future Outlook: With new filings from companies like SpaceX, more IPO transactions are expected in the coming months as the market broadens, and strong returns alongside a solid pipeline set the stage for a busy IPO calendar ahead.
See More
Latest Rating Changes on Wall Street
- Executive Rating Updates: Goldman Sachs initiates coverage on HawkEye 360 with a Buy rating, emphasizing its status as a profitable RF signals intelligence satellite operator, which is expected to achieve substantial revenue and earnings growth, reflecting strong confidence in its market potential.
- Dell Rating Upgrade: Morgan Stanley upgrades Dell from Underweight to Equal Weight, admitting prior market expectations were incorrect, highlighting Dell's superior supply chain management and execution compared to peers, enabling effective capture of critical demand and market share gains.
- MedTech Company Upgrade: Wells Fargo upgrades Tandem Diabetes Care to Overweight, citing an attractive risk/reward profile in the medical technology sector, indicating optimism about its future growth potential.
- Microsoft Market Performance Initiation: Citizens initiates Microsoft with a Market Outperform rating and a $550 price target, reflecting strong market performance potential despite a 7% decline year-to-date, indicating resilience in its business model.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Suja Life Raises $187 Million in IPO at Low End of Range
- Funding Size: Suja Life successfully raised $187 million by offering 8.9 million shares at $21 each, which is at the low end of the $21 to $24 range, indicating sustained market interest and demand for health-oriented beverages.
- Product Portfolio: The company focuses on functional and health-oriented drinks, with brands including Suja Organic, Vive Organic, and Slice, offering cold-pressed juices, wellness shots, and functional sodas designed for various consumption occasions, enhancing its competitive edge in the market.
- Production Capacity: Suja Life operates a vertically integrated cold-pressed beverage manufacturing facility in North America, ensuring high product quality and supply chain stability, thereby strengthening its position in the rapidly growing health beverage market.
- IPO Details: Based in Oceanside, CA, Suja Life will trade on Nasdaq under the ticker SUJA, with joint bookrunners including Goldman Sachs, Jefferies, and William Blair, reflecting strong backing in the capital markets.
See More
Suja Life Plans $200 Million IPO for Health-Oriented Beverage Platform
- IPO Fundraising Goal: Suja Life aims to raise $200 million by offering 8.9 million shares (2% secondary) at a price range of $21 to $24, intending to enhance its competitiveness in the health beverage market.
- Product Diversification: The company offers cold-pressed juices, wellness shots, and functional sodas through its Suja Organic, Vive Organic, and Slice brands, catering to various consumption occasions and solidifying its market position in functional beverages.
- Financial Performance: Suja Life reported $327 million in revenue for the 12 months ending December 31, 2025, indicating strong growth potential in the health beverage sector, with the IPO expected to provide funding for future expansion.
- Listing Plans: Suja Life plans to price its IPO during the week of May 4, 2026, and list on Nasdaq under the ticker SUJA, which is anticipated to attract investor interest in the health beverage industry.
See More
